aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
10. November 2022 16:00 ET
|
aTyr Pharma, Inc.
First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards largest value...
aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
06. September 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO , Sept. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
16. Mai 2022 08:00 ET
|
aTyr Pharma, Inc.
Global pivotal EFZO-FIT™ study expected to begin in the third quarter of 2022 Primary endpoint will evaluate steroid sparing effect of efzofitimod compared to placebo SAN DIEGO, May 16, 2022 ...
aTyr Pharma to Present at Upcoming Investor Conferences in May
10. Mai 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA...
aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
09. Mai 2022 16:00 ET
|
aTyr Pharma, Inc.
Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study of efzofitimod...
aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results
02. Mai 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25. März 2022 16:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Present at BIO CEO & Investor Conference
07. Februar 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Present at Upcoming Investor Conferences in November
12. November 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...